有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Everolimus;RAD-001;NVP-RAD-001;SDZ-RAD;Certican
Chemical Name [1R,9S,12S[1R(1S,3R,4R)],15R,18R,19R,21R,23S,30S,32S,35R]-1,18-Dihydroxy-12-[2-[4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16(E),24(E),26(E),28(E)-tetraene-2,3,10,14,20-pentaone
      40-O-(2-Hydroxyethyl)rapamycin
      (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1(R)-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentaone
CAS 159351-69-6
Related CAS
Formula C53H83NO14
Structure
Formula Weight 958.25076
Stage 上市-2004
Company Novartis (Originator), Guidant (Licensee)
Activity/Mechanism Antiarthritic Drugs, CARDIOVASCULAR DRUGS, IMMUNOMODULATING AGENTS, Immunosuppressants, Oncolytic Drugs, Restenosis Treatment of, Rheumatoid Arthritis, Treatment of, Solid Tumors Therapy, Treatment of Disorders of the Coronary Arteries and Atherosclerosis, TREATMENT OF MUSCULOSKELETAL & CONNECTIVE TISSUE DISEASES, Treatment of Transplant Rejection, Inhibitors of Signal Transduction Pathways, mTOR Inhibitors, Rapamycins, Rotamase (FKBP12) Inhibitors
Syn. Route 4
Route 1
alkylation of rapamycin (i) with 2-(tert-butyldimethylsilyloxy)ethyl triflate (ii) by means of 2,6-lutidine in hot toluene gives the silylated target compound (iii), which is deprotected by means of 1n hcl in methanol.
List of intermediates No.
1-allyl-5-bromo-4-azepanone (i)
7-chloro-5-(2-chlorophenyl)-1-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-4-ium-4-olate (ii)
7-chloro-5-(2-chlorophenyl)-1-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl acetate (iii)
Reference 1:
    casta?er, j.; sorbera, l.a.; leeson, p.a.; sdz-rad. drugs fut 1999, 24, 1, 22.
Reference 2:
    cottens, s.; sedrani, r. (novartis ag; novartis deutschland gmbh); o-alkylated rapamycin derivs. and their use, particularly as immunosuppressants. ep 0663916; ep 0867438; jp 1996502266; jp 1999240884; us 5665772; wo 9409010 .

Route 2
the compound has been obtained biosynthetically by an optimized fermentation process using streptomyces hygroscopicus mutant rsh 1701 with a complex culture medium were [14c]-labeled (1r,3r,4r)-2,3-dichydroxycyclo-hexanecarboxylic acid (i) and [14c]-labeled (s)-pipecolic acid (ii) have been added. this fermentation process yielded [14c]-labeled rapamycin (iii), which was finally selectively o-alkylated at the c-40 position with monosilylated ethylene glycol triflate in dmso/dimethoxyethane.
List of intermediates No.
(1s,2s)-3-amino-1-(2-ethoxyphenoxy)-1-phenyl-2-propanol (ii)
1-allyl-5-bromo-4-azepanone (iii)
(1s,3z,8s,9s,10r,11r)-9-(benzyloxy)-11-[[tert-butyl(dimethyl)silyl]oxy]-8,10,12,12-tetramethyl-1-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-13-oxo-3-tridecenyl acetate (i)
{(2r,3r,5r)-3-(acetyloxy)-4-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (i)
{(2r,4s,5r)-4-(acetyloxy)-3-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (ii)
{(2r,3r,5r)-3-(acetyloxy)-4-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl acetate (iii)
Reference 1:
    moenius, t.; et al.; c-14 labelling of nvp rad001 - a new rapamycin derivative. j label compd radiopharm 1999, 42, 1, 29.

Route 3
the reaction of the labeled acylated (+)-bornane-10,2-sultam (iv) with triethyl phosphite gives the phosphonate (v), which is treated with paraformaldehyde, galvinoxyl and k2co3 yielding the acrylate derivative (vi). the cyclization of (vi) with butadiene (vii) by means of diethylaluminum chloride and galvinoxyl (as radical scavenger) affords the cyclohexene-carboxamide derivative (viii), which is hydrolyzed with lioh in thf/water giving the (1r)-3-cyclohexenecarboxylic acid (ix). the oxidation of (ix) with m-chloroperbenzoic acid and triethylamine in ccl4 yielded regioselectively the hydroxylactone (x), which is finally hydrolyzed with hcl to the labeled intermediate (i).
List of intermediates No.
4-hydroxy-1-indanone (x)
(2r)-2-([[(2s)-1-(tert-butoxycarbonyl)pyrrolidinyl]carbonyl]amino)propionic acid (vii)
(2r)-2-([[(2s)-1-((2s)-2-[(tert-butoxycarbonyl)amino]-6-[[(ethylamino)(ethylimino)methyl]amino]hexanoyl)pyrrolidinyl]carbonyl]amino)propionic acid (ix)
(1s,3z,8s,9s,10r,11r)-9-(benzyloxy)-11-[[tert-butyl(dimethyl)silyl]oxy]-8,10,12,12-tetramethyl-1-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-13-oxo-3-tridecenyl acetate (i)
1-isopropoxyvinyl trimethylsilyl ether; [(1-isopropoxyvinyl)oxy](trimethyl)silane (iv)
isopropyl (3s,5r,6r,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-5-[[tert-butyl(dimethyl)silyl]oxy]-3-hydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-12,16-heptadecadienoate (v)
isopropyl (3s,5r,6s,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-3,5-dihydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-12,16-heptadecadienoate (vi)
isopropyl (3s,5r,6s,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-3-[[tert-butyl(dimethyl)silyl]oxy]-5-hydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-12,16-heptadecadienoate (viii)
{(2r,3r,5r)-3-(acetyloxy)-4-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (i)
{(2r,5r)-4-(acetyloxy)-3-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl acetate (iv)
{(2s,5r)-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methyl acetate (v)
{(2s,5r)-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (vi)
2-({(2s,5r)-5-[5-fluoro-2-oxo-4-(1h-1,2,4-triazol-1-yl)-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methoxy)-1,1-dimethyl-2-propenyl acetate (viii)
2-({(2s,5r)-5-[4-amino-5-fluoro-2-oxo-1(2h)-pyrimidinyl]-2,5-dihydro-2-furanyl}methoxy)-1,1-dimethyl-2-propenyl acetate (ix)
1-(tert-butyl) 3-methyl 5,6-dihydro-1,3(2h)-pyridinedicarboxylate (x)
Reference 1:
    moenius, t.; et al.; c-14 labelling of nvp rad001 - a new rapamycin derivative. j label compd radiopharm 1999, 42, 1, 29.

Route 4
the reaction of the labeled acylated (-)-bornane-10,2-sultam (xi) with benzophenone imine (xii) gives the glycylsultam derivative (xiii), which is alkylated with 4-iodobutyl chloride (xiv) by means of butyllithium and dmpu in thf yielding intermediate (xv). the selective hydrolysis of (xv) with hcl affords the omega-chloro-l-norleucine derivative (xvi), which is cyclized by means of tetrabutylammonium fluoride and diea in hot acetonitrile giving the (2s)-piperidyl derivative (xvii). finally, this compound is hydrolyzed with lioh in thf/water to the labeled intermediate (ii).
List of intermediates No.
(1s,2s)-3-amino-1-(2-ethoxyphenoxy)-1-phenyl-2-propanol (ii)
isopropyl (3s,6r,7s,8s,12z,15s,16e)-15-(acetoxy)-7-(benzyloxy)-3-[[tert-butyl(dimethyl)silyl]oxy]-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-5-oxo-12,16-heptadecadienoate (xii)
(3s,6r,7s,8s,12z,15s,16e)-7-(benzyloxy)-3-[[tert-butyl(dimethyl)silyl]oxy]-15-hydroxy-4,4,6,8,16-pentamethyl-17-(2-methyl-1,3-thiazol-4-yl)-5-oxo-12,16-heptadecadienoic acid (xiii)
(4s,7r,8s,9s,16s)-8-(benzyloxy)-4-[[tert-butyl(dimethyl)silyl]oxy]-5,5,7,9-tetramethyl-16-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]oxa-13-cyclohexadecene-2,6-dione (xiv)
3-(benzyloxy)-2,2-dimethylpropanal (xv)
(e)-7-(benzyloxy)-6,6-dimethyl-4-hepten-3-one (xvi)
1-[3-[2-(benzyloxy)-1,1-dimethylethyl]-2-oxiranyl]-1-propanone (xvii)
1-[3-[2-(benzyloxy)-1,1-dimethylethyl]-2-oxiranyl]-1-propanone o-methyloxime (xi)
{(2r,4s,5r)-4-(acetyloxy)-3-bromo-5-[5-fluoro-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl}methyl 2-(acetyloxy)-2-methylpropanoate (ii)
1-(tert-butyl) 3-methyl 3,6-dihydro-1,3(2h)-pyridinedicarboxylate (xiii)
tert-butyl 3-(hydroxymethyl)-3,6-dihydro-1(2h)-pyridinecarboxylate (xv)
tert-butyl 5-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (xvi)
(3s,4r,5s)-3-(hydroxymethyl)-5-methyl-4-piperidinol (xvii)
(3r,4r,5r)-5-(hydroxymethyl)-3,4-piperidinediol (xi)
Reference 1:
    moenius, t.; et al.; c-14 labelling of nvp rad001 - a new rapamycin derivative. j label compd radiopharm 1999, 42, 1, 29.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名依维莫司;英文名Everolimus;RAD-001;NVP-RAD-001;SDZ-RAD;Certican;CAS[159351-69-6]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
新农药登记需要注意哪些问题?
2018年除草剂登记数量领先,
江苏省严查严管危废处置,保障环
年报!正邦科技净利润或同比下降
中山化工嘧菌酯/灭草松/啶酰菌
红太阳子公司重庆华歌生化投资设
吲唑磺菌胺化合物专利已经届满,
2019年上海市推荐农药品种及
预增!江山/新安2018年净利
国光股份募集资金投资项目变更实
安道麦与辉丰签署备忘录,拟收购
恭喜!这3家企业入围第25批国
科迪华旗下喹禾灵除草剂产品线被
民族骄傲!氰烯菌酯再获国家科学
BMS 白血病药物组合 Spr
增加至7000万!国光股份子公
农药领域的行政许可事项相互之间
暂停?不存在的!2019年将全
多个植保农药类项目拟提名201
又有多项植保农药类成果拟提名2
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明